Biotech Values

[ombowstring]

I've learned that the mixed shelf offering that AXSM filed for on December 5th must be approved by the SEC before any shares can be sold.

This is from Informed Investor on the Yahoo message board for AXSM -

>>1. SEC Rule 415 Shelf Registration Statements set out the amount of capital the Company expects to raise via debt and equity offerings over the next 2 YEARS. This is the appropriate and necessary next step as AXSM is no longer a development stage company under the SEC’s emerging company guidelines.
2. The Company’s shelf registration statement has to be reviewed and approved by the SEC which will likely take until the end of the year so there can be no sale of debt or equity until the Rule 415 Shelf is approved. Further, the SEC specifically instructs Shelf Registrants to file for the amount the registrant expects to raise over a two year period. The SEC also instructs companies to refrain from drawing down the entirety of the shelf in a single transaction. Translation: it is highly unlikely there will an equity offering before the end of the year and AXSM is unlikely to raise the entire $80MM in a single transaction when it ultimately elects to use its Shelf.<<

AXSM is targeting numerous indications with their drugs. Already,

>>Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy<<

and

>>Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder<<

source - https://axsometherapeuticsinc.gcs-web.com/news-releases?field_nir_news_date_value[min]=2019

Pipeline -

https://axsome.com/axs-pipeline/overview/

https://axsome.com/axs-pipeline/axsome-pain-and-primary-care/

There could be significant further appreciation of the stock (I'm guessing $200-$250 a share, but don't go solely by me).

The immediate direction of the share price is almost certainly dependent upon the the results of the trial of AXS-07 for migraine headaches. Those results are scheduled to be announced by year's end.